Compare BLCO & MKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BLCO | MKTX |
|---|---|---|
| Founded | 1853 | 2000 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Ophthalmic Goods | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 6.0B |
| IPO Year | 2022 | 2004 |
| Metric | BLCO | MKTX |
|---|---|---|
| Price | $16.19 | $180.04 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 9 |
| Target Price | $18.55 | ★ $204.44 |
| AVG Volume (30 Days) | 444.0K | ★ 461.9K |
| Earning Date | 05-21-2026 | 05-11-2026 |
| Dividend Yield | N/A | ★ 1.72% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 6.64 |
| Revenue | ★ $5,101,000,000.00 | $397,471,000.00 |
| Revenue This Year | $8.61 | $10.06 |
| Revenue Next Year | $5.52 | $7.20 |
| P/E Ratio | ★ N/A | $27.34 |
| Revenue Growth | 6.47 | ★ 7.45 |
| 52 Week Low | $10.45 | $156.17 |
| 52 Week High | $18.92 | $232.84 |
| Indicator | BLCO | MKTX |
|---|---|---|
| Relative Strength Index (RSI) | 34.79 | 48.71 |
| Support Level | $14.39 | $177.38 |
| Resistance Level | $17.44 | $183.23 |
| Average True Range (ATR) | 0.52 | 4.50 |
| MACD | -0.21 | -1.12 |
| Stochastic Oscillator | 3.47 | 22.26 |
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
Founded in 2000, MarketAxess is a leading electronic fixed-income trading platform that connects broker/dealers and institutional investors. The company is primarily focused on credit based fixed income securities with its main trading products being US investment-grade and high-yield bonds, Eurobonds, and Emerging Market corporate debt. Recently the company has expanded more aggressively into Treasuries and municipal bonds with the acquisitions of LiquidityEdge and MuniBrokers in 2019 and 2021, respectively. The company also provides pre- and post-trade services with its acquisition of Regulatory Reporting Hub from Deutsche Börse Group in 2020 adding to its product offerings.